The group’s principle activity is to develop therapeutic modalities and small molecule compounds. The group also initiated discovery and optimization of second-generation NEXT(TM) lead compounds specific for HIV-1 and other chronic viruses including HBV, HDV, HPV, CMV and Influenza. The group operates from United States.
